DARZALEX FASPRO J Code: J9144

Drug & Product Overview

HCPCS Descriptor Injection, daratumumab, 10 mg and hyaluronidase-fihj

HCPCS Added Date January 1, 2021

Manufacturer Janssen

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About DARZALEX FASPRO

Darzalex Faspro is a medication aligned to the HCPCS J Code: J9144 for billing, pricing, and reimbursement purposes in the United States. This Oncology medication is administered via the subcutaneous route and manufactured by Janssen.

According to CMS Drug Use Information: This medication is used to treat a certain type of cancer (multiple myeloma). This medication contains 2 ingredients: daratumumab and hyaluronidase. Daratumumab belongs to a class of drugs known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Hyaluronidase is used to help the body absorb daratumumab, which helps it work better. This medication is also used to treat light chain (AL) amyloidosis. This monograph is about the following daratumumab/hyaluronidase products: daratumumab/hyaluronidase, daratumumab/hyaluronidase-fihj.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
57894-0503-01	Darzalex Faspro	Janssen Biotech, Inc.	180	1800 MG / 15 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

DARZALEX FASPRO Pricing & Reimbursement

J9144 Private Payer Reimbursement

$57.25 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

DARZALEX FASPRO CPT Administration Codes

CPT Code	Description
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic

JW / JZ modifiers apply

CMS has identified Darzalex Faspro (J9144) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

DARZALEX FASPRO Medically Unlikely Edits (MUE)

The most billing units of J9144 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient

180 units / day

= 1,800 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

DARZALEX FASPRO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

High-Risk Smoldering Multiple Myeloma Light Chain (AL) Amyloidosis Multiple Myeloma

Drug Class

AntibodiesMonoclonal [CS]CD38-directed Antibody Interactions [MoA]CD38-directed Cytolytic Antibody [EPC]Endoglycosidase [EPC]Glycoside Hydrolases [CS]

Frequently Asked Questions

Is there an available Darzalex Faspro billing and coding guide?

Billing and coding information for DARZALEX FASPRO can be found through Janssen. Visit Here →

Are there any available Darzalex Faspro patient assistance programs?

DARZALEX FASPRO patient assistance information can be found through Janssen. Visit Here →

Where can I find Darzalex Faspro prescribing information?

DARZALEX FASPRO prescribing information can be found at the link below: Visit Here →

Where can I find Darzalex Faspro side effect information?

Information regarding DARZALEX FASPRO's side effects can be found at MedlinePlus Visit Here →

Does billing DARZALEX FASPRO require JZ/JW wastage modifiers?

CMS has identified DARZALEX FASPRO(J9144) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.